Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function

Area of Science:

• Pulmonology
• Immunology
• Clinical Medicine

Background:

• Severe asthma management remains challenging.
• Biologic therapies offer targeted treatment options.
• Evaluating treatment adjustments like biologic switching is crucial for optimizing patient care.

Purpose of the Study:

• To assess the real-world clinical effectiveness of biologic switching in adults with severe asthma.
• To compare outcomes before and after switching biologic agents.
• To identify specific biologic switch combinations associated with improved outcomes.

Main Methods:

• Retrospective analysis of 29 adult severe asthma patients undergoing biologic switching.
• Comparison of asthma exacerbations, systemic corticosteroid use, asthma control, and spirometry pre- and post-switch.
• Subgroup analyses based on specific biologic switch pathways (e.g., omalizumab to mepolizumab).

Main Results:

• Biologic switching significantly reduced median annual exacerbation rates (2.0 to 0) and systemic corticosteroid use (69.0% to 34.5%).
• Switching from omalizumab to mepolizumab showed significant improvements in exacerbations, corticosteroid use, and asthma control.
• Switching from mepolizumab to benralizumab also decreased exacerbation rates, though corticosteroid use changes were not significant.

Conclusions:

• Biologic switching is a viable strategy for selected severe asthma patients with inadequate response to initial biologic therapy.
• Favorable clinical outcomes, including reduced exacerbations and better asthma control, were observed post-switch.
• The effectiveness of biologic switching may vary depending on the specific agents involved in the switch.